Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset
Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG1051, a pre-clinical investigational novel compound with broad potential to treat brain